Diabetes and the GI Tract: From Gastroparesis to NAFLD
Introduction Diabetes is a systemic disease with well-known effects on the eyes, kidneys, and cardiovascular system, but its impact on the gastrointestinal (GI) tract is often underrecognized. In clinical practice, patients with diabetes frequently report symptoms such as bloating, nausea, reflux, constipation, or alternating bowel habits, yet these complaints are rarely attributed directly to glycemic […]
Pharmacologic Treatment of MASLD/MASH: GLP-1 Agonists, Resmetirom & Beyond
Rebranding NAFLD/NASH → MASLD/MASH: Why the New Terminology Matters In 2023, a major nomenclature shift redefined the landscape of fatty liver disease: NAFLD (nonalcoholic fatty liver disease) became MASLD (metabolic dysfunction-associated steatotic liver disease), and NASH (nonalcoholic steatohepatitis) was renamed MASH (metabolic dysfunction-associated steatohepatitis). This reclassification, endorsed by hepatology societies including the AASLD in its […]